STOCK TITAN

Flyte Achieves Record Revenues in July

(Very Positive)
Tags

Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), reported preliminary record monthly revenue of approximately $640,000 for July 2026, a 102% sequential increase over June, marking the strongest operating month in Flyte’s history as demand rises on its private aviation platform.

Since relaunching its direct-to-consumer platform, Flyte has added 2,700+ new users, supported by strategic partnerships, digital marketing, and influencer campaigns. In 2026 it expanded partnerships with Blade, Vaunt, Volato AI (NYSE American: SOAR), GSE Worldwide & Emiliano Grillo, LifeVac, and LDV at The Maidstone. Catheter Precision emphasized that June and July 2026 revenue figures are preliminary, unaudited estimates and remain subject to change.

Loading...
Loading translation...

Positive

  • July 2026 revenue ~$640,000, up 102% vs June 2026
  • Record monthly revenue, strongest operating month in Flyte’s history
  • 2,700+ new users acquired since relaunch of direct-to-consumer platform
  • Multiple 2026 partnerships across aviation, hospitality, sports, healthcare, and luxury brands
  • Volato AI (SOAR) partnership to integrate advanced aviation technology solutions

Negative

  • June and July 2026 revenues are preliminary, unaudited and may need material adjustments

Market reaction after July 2026 earnings report: VTAK +7.57%

+7.57% $0.29 1.5x vol
15m delay
+7.57% Vs previous close
+35.1% Peak in 2 min
$0.29 Last Price
$0.26 $0.42 Day Range
$1.05M Market Cap
1.5x Rel. Volume

Following this news, VTAK has gained 7.57%, reflecting a notable positive market reaction. Argus tracked a peak move of +35.1% during the session. Our momentum scanner has triggered 36 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.29. Trading volume is above average at 1.5x the average, suggesting increased trading activity.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

A prior LifeVac partnership announcement had a 92.23% 24-hour reaction, while other updates diverged...
Analysis

A prior LifeVac partnership announcement had a 92.23% 24-hour reaction, while other updates diverged. The July revenue report adds operating evidence, but preliminary figures and high short positioning remain risks to monitor.

Key Figures

July revenue: $640,000 Sequential revenue growth: 102% New users: more than 2,700 users
3 metrics
July revenue $640,000 July 2026 preliminary monthly revenue
Sequential revenue growth 102% July 2026 versus June 2026
New users more than 2,700 users Since relaunching the direct-to-consumer platform

Historical Context

5 past events · Latest: Jul 27 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jul 27 Golf partnership Positive +10.4% Exclusive private aviation partnership with 319 Golf Society; shares rose 10.39%.
Jul 22 Blade partnership Positive -21.0% Blade distribution partnership announced; shares fell 21.04%.
Jul 21 Blade partnership Positive -21.0% Blade platform partnership announced; shares fell 21.04%.
Jul 15 Revenue update Positive +3.6% Preliminary second-quarter revenue exceeded $1 million; shares rose 3.57%.
Jul 07 LifeVac partnership Positive +92.2% LifeVac devices added to every Vision Jet; shares rose 92.23%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Flyte's recent partnership and operating updates showed mixed reactions, with three aligned positive moves and two divergences.

Key Terms

part 135, generally accepted accounting principles, unaudited financial statements, non-powered airway clearance device
4 terms
part 135 regulatory
"FAA-certified Part 135 operating subsidiary, Ponderosa Air, LLC"
Part 135 is the section of U.S. aviation regulations that governs on-demand and small commercial air operations, such as charter flights, air taxis and some commuter services. For investors, Part 135 status signals the level of safety oversight, operating limits, insurance requirements and costs a company faces—think of it like a business license tier that dictates what routes, aircraft and customers a carrier can serve and how much it costs to run safely and legally.
generally accepted accounting principles financial
"prepared in accordance with accounting principles generally accepted in the United States"
Generally accepted accounting principles (GAAP) are a standardized set of rules and practices companies use to record and report their financial results, like a common recipe so dishes from different cooks can be fairly compared. Investors rely on GAAP because it makes company earnings, assets and liabilities consistent and transparent across businesses, helping them compare performance, spot risks, and make informed decisions about buying or selling stock.
unaudited financial statements financial
"substitute for full unaudited financial statements"
Unaudited financial statements are company-prepared reports of financial activity—such as income, expenses, assets and liabilities—that have not been examined or certified by an independent auditor. They offer a quicker, internal snapshot of performance, like a homeowner’s informal monthly budget compared with a bank-verified tax return. Investors use them to track recent trends and short-term results, but they carry less external verification than audited statements.
non-powered airway clearance device medical
"the first FDA-authorized non-powered airway clearance device"
A non-powered airway clearance device is a handheld or mask-based medical tool that helps patients loosen and remove mucus from the lungs using the user's own breathing mechanics, valves, or simple mechanical parts rather than electricity or batteries. It matters to investors because this product category represents a segment of respiratory care with distinct regulatory pathways, reimbursement rules, manufacturing costs, and adoption patterns that can influence sales, margins, and market potential for companies in medical device and home-care markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

July 2026 Revenue Increased 102% sequential July Over June to Approximately $640,000

Retail Platform, Strategic Partnerships and Influencer Marketing Fuel Accelerating Growth

FORT MILL, S.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK”), today announced record monthly revenue for July 2026, marking the strongest operating month in Flyte’s history as demand continues to accelerate across its private aviation platform.

Since launching its enhanced direct-to-consumer platform, Flyte has acquired more than 2,700 new users, reflecting continued demand for the Company's technology-enabled booking platform and growing awareness of the Flyte brand. The expanding user base has been supported by strategic partnerships, targeted digital marketing, and influencer initiatives that continue to drive customer acquisition across multiple distribution channels.

July 2026 Highlights

  • Highest revenue month in Flyte’s history
  • Revenue increased 102% versus June 2026
  • Acquired more than 2,700 new users since relaunching Flyte's direct-to-consumer platform

The record results were driven by the continued success of Flyte’s direct-to-consumer retail platform, combined with an expanding network of strategic partnerships and influencer marketing initiatives that are driving significant increases in brand awareness, customer acquisition, and flight bookings.
During 2026, Flyte significantly expanded its commercial ecosystem through strategic partnerships spanning hospitality, aviation, healthcare, sports, technology, and luxury lifestyle brands, including:

  • Blade: Partnered with the world's leading helicopter passenger transportation company to expand premium travel options and enhance private aviation connectivity.
  • Vaunt: Partnered with Volato's experiential private aviation platform to expand customer acquisition, increase empty leg utilization, and create reciprocal travel benefits for Flyte and Vaunt members.
  • Volato AI (NYSE American: SOAR): Partnered with Volato AI to integrate advanced aviation technology solutions designed to enhance operational efficiency and support Flyte's continued technology-driven growth strategy.
  • GSE Worldwide & Emiliano Grillo: Partnered with one of the world's leading sports and entertainment agencies and PGA TOUR professional Emiliano Grillo to expand Flyte's reach among elite athletes, entertainers, executives, and premium lifestyle clients.
  • LifeVac: Partnered with the developer of the first FDA-authorized non-powered airway clearance device to equip Flyte aircraft with LifeVac emergency choking response devices.
  • LDV at The Maidstone: Partnered with East Hampton’s iconic luxury boutique hotel to provide guests with seamless private aviation access and exclusive travel experiences.

“Our July performance validates the strategy we’ve been executing over the past several months,” said David Jenkins, Chief Executive Officer of Catheter Precision. “Our retail platform is gaining traction, our strategic partnerships are producing measurable customer growth, and our influencer marketing initiatives are accelerating user acquisition. Since relaunching our platform, we have acquired more than 2,700 new users, reinforcing our belief that we are building a scalable customer acquisition engine alongside a growing private aviation business. Most importantly, we believe we’re still in the early stages of Flyte’s growth trajectory.”

Flyte continues to expand its fleet, operating footprint, strategic partnerships, customer base, and geographic reach as it executes its long-term strategy to build a leading technology-enabled private aviation platform.

About Flyte
Flyte is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the United States. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary, Ponderosa Air, LLC, Flyte is delivering a faster, safer, and more convenient private aviation experience.

For more information, visit www.flyflyte.com.

Preliminary June and July 2026 Results

This press release sets forth certain preliminary estimates of revenue that we expect to report for the months of June and July of 2026. This information should not be viewed as a substitute for full unaudited financial statements prepared in accordance with accounting principles generally accepted in the United States contained in our periodic reports filed with the Securities and Exchange Commission. Our independent registered public accounting firm has not reviewed this preliminary estimated financial information. As a result, it remains in all cases subject to change pending finalization. Items or events may be identified or occur after issuance of these preliminary results due to the completion of operational and financial closing procedures. In addition, final adjustments and other developments may arise that would require us to make material adjustments to these preliminary revenue numbers.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  Statements that are not historical facts, including statements regarding expected future operating performance, growth, demand, customer acquisition, booking trends, and strategic partnerships are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

Contact
Investor Relations
IR@Catheterprecision.com


FAQ

How much did Flyte’s July 2026 revenue grow for Catheter Precision (VTAK)?

Flyte’s preliminary July 2026 revenue is about $640,000, a 102% sequential increase over June. According to Catheter Precision, this represents the strongest operating month in Flyte’s history and reflects accelerating demand on its technology-enabled private aviation platform.

Why is Flyte’s July 2026 performance important for Catheter Precision stock (VTAK)?

Flyte delivered record preliminary July 2026 revenue of about $640,000, up 102% versus June. According to Catheter Precision, Flyte’s fastest-ever operating month and growing user base highlight momentum in its private aviation business, which may be relevant for VTAK investors monitoring subsidiary growth.

How many new users did Flyte add to its private aviation platform in 2026?

Flyte has acquired more than 2,700 new users since relaunching its direct-to-consumer booking platform. According to Catheter Precision, this user growth is driven by the retail platform, strategic partnerships, targeted digital marketing, and influencer initiatives that expand customer acquisition across multiple distribution channels.

Which 2026 strategic partners support Flyte’s growth, including Volato AI (SOAR)?

In 2026, Flyte added partners including Blade, Vaunt, Volato AI (NYSE American: SOAR), GSE Worldwide & Emiliano Grillo, LifeVac, and LDV at The Maidstone. According to Catheter Precision, these partnerships expand premium travel options, brand reach, safety capabilities, and access to high-value customer segments.

Are Flyte’s June and July 2026 revenue figures for Catheter Precision (VTAK) final?

No. The June and July 2026 revenue numbers are preliminary, unaudited estimates. According to Catheter Precision, they have not been reviewed by the independent registered public accounting firm and remain subject to change, including potential material adjustments after full closing procedures.

What is Flyte and how does it fit into Catheter Precision’s (VTAK) business?

Flyte is a technology-enabled private aviation company and subsidiary of Catheter Precision (VTAK). According to Catheter Precision, Flyte operates a growing Cirrus Vision Jet fleet via FAA-certified Part 135 carrier Ponderosa Air, using a direct-to-consumer platform and partnerships to deliver standardized, efficient private air travel.